Abstract
The pharmaceutical industry is a typically research-intensive, first world-industry. This article seeks to explain why it has been so difficult for late industrialised nations to reproduce the networks of innovation on which the design and manufacturing of new drugs has historically based, and why alternative concepts are needed in order to understand the dynamics of science-based industries in emerging countries. The article analyses the development of the Spanish antibiotics industry, built after the World War II under the strong influence of the new international order and Spain's political framework, academic traditions and business groups. Focusing on the long-term relationships established between two Spanish companies (Antibióticos SA and Compañia Española de Penicilina y Antibióticos, CEPA), their American technological partners (Schenley and Merck), and their social and scientific environment, the article identifies networks of opportunity as the key institutional arrangement of this new industry in Spain. Opportunity (as opposed to innovation) networks are thus proposed to conceptualise the development of technologically complex industries in the European periphery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
